Trial Profile
Safety and imunogenecity of Meningococcal B Vaccine (4CMenB, Bexsero) in Healthy adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 29 Sep 2016 New trial record